Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition

Pharmacotherapy

Volumn 25, Issue 12 I, 2005, Pages 1729-1735

  Kogut, Stephen J ^a   El Maouche, Diala ^a   Abughosh, Susan M ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Adherence; Alzheimer's disease; Cholinesterase inhibitors; Cognition; Dementia; Medicaid; Persistence

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ATROPINE; BELLADONNA ALKALOID; BENZATROPINE; BUTALBITAL; CARISOPRODOL; CHLORDIAZEPOXIDE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CIMETIDINE; CLIDINIUM; CLONAZEPAM; CLORAZEPATE; CLOZAPINE; CODEINE; CYCLOBENZAPRINE; CYPROHEPTADINE; DESIPRAMINE; DEXCHLORPHENIRAMINE; DIAZEPAM; DICYCLOVERINE; DIMENHYDRINATE; DIPHENHYDRAMINE; DOXEPIN; FENTANYL; FLUPHENAZINE; NEUROLEPTIC AGENT; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CAUCASIAN; CHOLINESTERASE INHIBITION; COGNITIVE DEFECT; COVARIANCE; DEMENTIA; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; IATROGENIC DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RACE DIFFERENCE; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MEDICAID; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; POLYPHARMACY; REGRESSION ANALYSIS; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 29044441116     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.12.1729     Document Type: Article

References (37)

1. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial: the donepezil study group. Dementia 1996;7:293-303.
2. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study: donepezil study group. Arch Intern Med 1998;158:1021-31.
3. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
4. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8.
5. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension: the galantamine USA-1 study group. Neurology 2000;54:2261-8.
6. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the galantamine USA-10 study group. Neurology 2000;54:2269-76.
7. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-16.
8. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can Med Assoc J 2003;169:557-64.
9. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8.
10. Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:295-300.
11. Matthews HP, Korbey J, Wilkinson DG, Rowden J. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000;15:713-20.
12. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-44.
13. Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44-54.
14. Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M. Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's disease cooperative study. Neurology 1999;52:714-18.
15. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease. Part II: treatment. Am Fam Physician 2002;65:2525-34.
16. American Medical Directors Association. Dementia. Columbia, MD: American Medical Directors Association, 1998.
17. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15-28.
18. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
19. Weiner MF, Edland SD, Luszczynska H. Prevalence and incidence of major depression in Alzheimer's disease. Am J Psychiatry 1994;151:1006-9.
20. Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. J Clin Psychiatry 2003;64:466-72.
21. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24.
22. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997;157:1531-6.
23. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001;161:1099-105.
24. Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003;11:458-61.
25. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed. Stamford, CT: Appleton & Lange, 2002.
26. Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill, 2001.
27. Aparasu RR, Sitzman SJ. Inappropriate prescribing for elderly outpatients. Am J Health-Syst Pharm 1999;56:433-9.
28. Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992;117:684-9.
29. Giron MS, Wang HX, Bernsten C, Thorslund M, Winblad B, Fastbom J. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc 2001;49:277-83.
30. Golden AG, Preston RA, Barnett SD, Llorente M, Hamdan K, Silverman MA. Inappropriate medication prescribing in homebound older adults. J Am Geriatr Soc 1999;47:948-53.
31. Hanlon JT, Fillenbaum GG, Schmader KE, Kuchibhatla M, Horner RD. Inappropriate drug use among community-dwelling elderly. Pharmacotherapy 2000;20:575-82.
32. Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002;50:26-34.
33. Stuck AE, Beers MH, Steiner A, Aronow HU, Rubenstein LZ, Beck JC. Inappropriate medication use in community-residing older persons. Arch Intern Med 1994;154:2195-200.
34. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey. JAMA 2001;286:2823-9.
35. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002;50:836-42.
36. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002;16:49-51.
37. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-6.